加载中
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
前收盘价
US$2.61
+US$0.01 · +0.38%
盘中时间采用ET。市场数据可能有所延迟。
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
日内区间
当前US$2.61
52周区间
当前US$2.61
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
42
合理估值
情绪
59
多空交织
风险
54
风险偏高
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
日内区间
当前US$2.61
52周区间
当前US$2.61
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.1万 USD | 2万 USD | 42.6万 USD | −6.8万 USD | 441万 USD |
| 毛利 | 4.1万 USD | 2万 USD | 42.6万 USD | −6.8万 USD | 441万 USD |
| 研究与开发 | 6643.2万 USD | 8222.6万 USD | 6579.9万 USD | 7053.8万 USD | 7454.1万 USD |
| 销售、一般及管理费用 | 2809.8万 USD | 2096.6万 USD | 1813.7万 USD | 1713.4万 USD | 1541.3万 USD |
| 营业费用 | 9453万 USD | 1.03亿 USD | 9635.5万 USD | 8767.2万 USD | 1.01亿 USD |
| 利息收入 | 754.1万 USD | 807.4万 USD | 735.1万 USD | 287万 USD | 20.3万 USD |
| 利息支出 | 163.6万 USD | 9000 USD | 3.5万 USD | 8000 USD | 5000 USD |
| 折旧和摊销 | 11.2万 USD | 23.8万 USD | 47.7万 USD | 49.3万 USD | 55.1万 USD |
| 营业利润 | −9448.9万 USD | −1.03亿 USD | −9592.9万 USD | −8774万 USD | −9691.4万 USD |
| 净利润 | −8809.3万 USD | −9505.9万 USD | −8844.7万 USD | −8471.3万 USD | −9709万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.25
上涨空间 139.46%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2017年2月6日 | US$291Monthly | 2017年1月24日 | — |
股息 | 2017年1月20日 | US$291Monthly | 2017年1月24日 | 2017年2月3日 |
除息 2017年2月6日
US$291
Monthly
2017年1月24日登记
除息 2017年1月20日
US$291
Monthly
2017年1月24日登记 · 支付日 2017年2月3日
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1787.87万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1314.72万0.02%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1172.78万0.12%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF704.69万0.01%954亿 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM381.4万0.06%64.1亿 USD0.28%US$45.46+0.46%
iShares Biotechnology ETFIBB378.66万0.04%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO355.33万0.02%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC157.73万0.12%13.17亿 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
